Physician profile
Charles E Bruce
NPI 1609868140
$2,791.44
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $174 · 2021: $529 · 2022: $244 · 2023: $780 · 2024: $63.23 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $445.01 | 2019-2023 | Cequa |
| Coopervision INC. | $355.04 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Allergan, INC. | $329.62 | 2019-2020 | |
| Biotissue Holdings INC. | $284.01 | 2023 | |
| Kala Pharmaceuticals, INC. | $240.10 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.53 | 2019 | |
| Bausch & Lomb Americas INC. | $122.04 | 2023 | Miebo |
| Oyster Point Pharma, INC. | $121.81 | 2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $120.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.05 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $109.23 | 2025 | Xdemvy |
| Alcon Vision LLC | $107.16 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $105.86 | 2022-2025 | |
| Dompe US, INC. | $92.78 | 2021 | |
| Lkc Technologies, INC. | $71.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.